| Ytd | 100.66% | |
| 1y | 142.54% |
| Open | 12.59 | Prev Close | 12.70 | Low | 12.14 | High | 12.74 | Mkt Cap | 758.28M |
| Vol | 1.14M | Avg Vol | 1.09M | EPS | -1.29 | P/E | N/A | Forward P/E | N/A |
| Beta | 1.29 | Short Ratio | 2.36 | Inst. Own | 62.77% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 12.47 | 200-d Avg | 7.94 | 1yr Est | 53.70 |
Silence Therapeutics plc (SLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference T
U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endp
Gainers iSpecimen (NASDAQ:ISPC) shares increased by 10.4% to $1.7 during Friday's after-market
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, (Nasdaq: SLN), (“Silence
The average of price targets set by Wall Street analysts indicates a potential upside of 140.1% in S
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Compan
Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight
Silence Therapeutics (NASDAQ: SLN) reported top-line results from its Phase II SANRECO trial of dive
Silence Therapeutics NASDAQ: SLN reported top-line results from its Phase II SANRECO trial of divesi
Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran i
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Compan
Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regul
Silence Therapeutics plc (NASDAQ:SLN) stock is trading higher on Monday after the company reported p
Silence Therapeutics reports positive Phase 2 SANRECO trial data for divesiran in polycythemia vera.
BWMN gained 55.1%, HZO rose 45.8%, ABCL gained 35.6%, SLN rose 34.3%, ACHR gained 19.5%, NESR gained
Gainers Jin Medical International (NASDAQ:ZJYL) stock rose 70.7% to $3.67 during Monday's pre-m
Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (sho
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing nov
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global c
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.09) per share which beat the anal
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, (Nasdaq: SLN), a global
Avalon Holdings (NYSE:AWX) shares rose 10.5% in pre-market trading after posting strong Q2 earnings
Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (sho
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, (Nasdaq: SLN), a global
Silence Therapeutics shares surge as investors eye key 2026 divesiran data, an advancing RNAi pipeli
Silence Therapeutics (SLN) was a big mover last session on higher-than-average trading volume. The l
I initiate Silence Therapeutics at a speculative Buy, driven by near-term divesiran/SLN124 catalysts
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher
Silence Therapeutics Plc (NASDAQ:SLN) stock rose Wednesday after Cantor Fitzgerald initiated coverag
Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major
Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Silence Therapeutics (NASDAQ:SLN)
U.S. stock futures mostly higher, Nasdaq futures gain 100+ points. Sophia Genetics (SOPH) falls afte
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Silence Therapeutics (NASDAQ:SLN)
Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh d
New analyses from the Phase 1 SANRECO study demonstrate potential improvements in PV symptoms and qu
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.11) per share which beat the anal
Urgent.ly shares surged in pre-market trading after agreement to be acquired by Agero for $5.50 per
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarte
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for it
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterl
Tuesday's session saw 286 companies set new 52-week lows.
On Monday, 147 stocks made new 52-week lows.
During Friday's session, 149 stocks hit new 52-week lows.